博仲盛景医药技术

Bozhong Shengjing is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence metabolic diseases, including non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity, as well as oncology. Leveraging its proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platforms, Bozhong Shengjing aims to develop best-in-class and first-in-class medicines. Its lead candidate, BZ-001, is a selective thyroid hormone receptor beta (THR-beta) agonist currently in clinical development for the treatment of NASH. The company's pipeline also includes a small molecule GLP-1 receptor agonist and an SHP2 inhibitor. Bozhong Shengjing is led by a team of industry veterans with significant experience in global pharmaceutical R&D.